652976-28-8

Usage

Uses

Used in Pharmaceutical Industry:
(E)-5-HYDROXY-7H-PYRIDO[2,3-B]AZEPIN-8(9H)-ONE is used as a potential therapeutic agent for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Its neuroprotective properties and potential role in disease treatment are currently under investigation.
Used in Research and Development:
(E)-5-HYDROXY-7H-PYRIDO[2,3-B]AZEPIN-8(9H)-ONE is used as a subject of study in research and development for its antioxidant, anti-inflammatory, and neuroprotective properties. Further research is ongoing to explore its therapeutic potential and biological effects, which could lead to the development of new drugs and treatments for various conditions.
Used in Nutraceutical Industry:
Due to its antioxidant properties, (E)-5-HYDROXY-7H-PYRIDO[2,3-B]AZEPIN-8(9H)-ONE may also be used as an ingredient in the nutraceutical industry for the development of dietary supplements and functional foods that promote health and well-being.

Upstream product

• 13362-26-0 2-aminopyridine-3-carboxylic acid ethyl ester 
• 5345-47-1 2-aminopyridin-3-carboxylic acid 
• 652976-27-7 5-hydroxy-8-oxo-8,9-dihydro-7H-pyrido[2,3-b]azepine-6-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

9- and 11-substituted 4-azapaullones are potent and selective inhibitors of African trypanosoma

Trypanosomes from the "brucei" complex are pathogenic parasites endemic in sub-Saharan Africa and causative agents of severe diseases in humans and livestock. In order to identify new antitrypanosomal chemotypes against African trypanosomes, 4-azapaullone

LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS

The present invention provides novel compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3β

Kenpaullone derivatives with a modified parent ring system were synthesized in order to develop kinase inhibitors with enhanced selectivity. Among the novel structures, 1-azakenpaullone was found to act as a selective GSK-3β versus CDK1 inhibitor. The charge distribution within the 1-azakenpaullone molecule is discussed as a possible explanation for the enhanced GSK-3β selectivity of 1-azakenpaullone compared to other paullone derivatives.

Evaluation and Comparison of 3D-QSAR CoMSIA Models for CDK1, CDK5, and GSK-3 Inhibition by Paullones

With a view to the rational design of selective GSK-3β inhibitors, 3D-QSAR CoMSIA models were developed for the inhibition of the three serine/threonine kinases CDK1/cyclin B, CDK5/p25, and GSK-3β by compounds from the paullone inhibitor family. The model